Keywords: cox-2, inhibitors, potential, colon, cancer, merck, co
COX-2 inhibitors: potential in colon cancer?
Article | 09 September 1999
- Merck & Co and Searle are investigating the potential of theirrespective COX-2 inhibitors, Vioxx (rofecoxib) and Celebrex (celecoxib), in a race ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
